In 1996, Dr Andrès received his MD degree in Internal Medicine, at the University of Strasbourg, France. He worked as an associated professor in the University Hospital of Strasbourg, France. In 1998 he worked as PhD in Molecular Biology in the Laboratory of Professor Hoffmann (2011, Nobel Prize of Medicine) in the field of cationic antimicrobial peptides and pathogens - host relations. In 2002, he was nominated Professor at the University of Strasbourg, France. He also was in the head of an Internal Medicine Department (of 62 beads) in the University hospital of Strasbourg, France. He was awarded the French Society of Haematology, price for research in the field of anaemia related to cobalamin or folate deficiencies in 2004. Achievements include development of research in: all type of anaemia, neutropenia and thrombocytopenia, particularly drug-induced neutropenia and agranulocytosis or thrombocytopenia; haematopoietic growth factors; and cobalamin deficiencies. He also conducts several studies on inflammatory or immune disorders. His recent works also include research and development on human sounds analysis, electronic stethoscope, e-auscultation, and e-medicine. In that function he was recruited as advisor to several pharmaceutical and telemedicine companies or start-up.
Systemic immune and inflammatory diseases
Drug-induced side effects
Ken He Young University of Texas , USA
Dr. Ken H. Young is Professor of the University of Texas MD Anderson Cancer Center. He obtained his MD degree in Medicine from Zhejiang University School of Medicine, Zhejiang, China, 1984, and PhD in Hematologyfrom University of Lund School of Medicine, Malmo, Sweden, PhD,1995. In 2003, he completed residency training at Oregon Health Science University and Pathology/Hematology fellowship at University of Nebraska Medical Center. In 2005, he worked as assistant Professor at the University ofWisconsin Hospital, Madison, Wisconsin. He has been awarded from the Lymphoma Leukemia Society and National Institute of Health/National Cancer Institute for clinical research in the field of lymphoma and myeloma related to genomic and phenotypic biomarkers. Since 2011, progresses include development of research in many different types of lymphoma andimmune dysregulatory disorders, particularly drug-induced resistance, cancer recurrence and prognosis, tumor microenvironment and B-cell signaling pathways. He also conducts studies on inflammatory or immune disorders related to cancer. His recent works include research and development on geneomic and epigenomic profiling of various subtypes of lymphoma and myeloma.